Zenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday both set estimated price ranges in their initial public offerings in a sign that the traditional summer lull in deals is coming to an end.
Add A Comment
Zenas BioPharma, Bicara Therapeutics sets IPO price ranges as summer lull ends
By